Abridge was founded in 2018 with the mission of powering deeper understanding in healthcare. Our AI-powered platform was purpose-built for medical conversations, improving clinical documentation efficiencies while enabling clinicians to focus on what matters most—their patients. Our enterprise-grade technology transforms patient-clinician conversations into structured clinical notes in real-time, with deep EMR integrations. Powered by Linked Evidence and our purpose-built, auditable AI, we are the only company that maps AI-generated summaries to ground truth, helping providers quickly trust and verify the output. As pioneers in generative AI for healthcare, we are setting the industry standards for the responsible deployment of AI across health systems.

Acelab is an all-in-one platform designed for architects and designers to research, specify, and manage building materials efficiently. The platform utilizes AI-driven tools to help users find the right products quickly, generate detailed comparisons, and manage project documentation seamlessly. Acelab differentiates itself by offering a free service for architects while providing manufacturers with subscription-based branding options. With over 15,000 firms trusting the platform, Acelab is positioned as a leading resource in the architecture and construction industry, streamlining the materials decision-making process and enhancing collaboration among project teams.

Adaptilens is a pioneering company focused on developing the first biomimetic accommodating intraocular lens (A-IOL) that mimics the natural lens of a young, healthy eye. Their innovative technology aims to revolutionize cataract surgery by providing a soft, flexible lens that restores a full range of vision without the need for glasses, addressing the limitations of traditional rigid lenses. With a significant market opportunity, given that over 30 million cataract surgeries are performed globally each year, Adaptilens is positioned to capture a substantial share of this growing market. The company has recently secured $17.5 million in Series A financing, indicating strong investor confidence and traction in the ophthalmic device sector.

DeFi that scales. Built on Algorand. YC S21. Earn interest, borrow, and trade your crypto.

Algorand is positioned to address the blockchain’s scaling challenges through rapid and efficient user consensus, enabling even the smallest transactions, regardless of transaction volume or number of users.

Building AI software development agents for everyone, in the open.

Share your knowledge. Effortlessly create, organize, and share knowledge-based content, powered by AI.

Aorist operates a cultural institution and a climate-forward NFT marketplace to provide a home for artists and collectors to explore creative digital art. It also offers conception to production support and its technology is custom-built for the art industry, delivering an easy-to-use collector experience. Additionally, it helps artists create cultural programs backed by updated technologies that guide them through the evolving digital landscape.

Asimov is a synthetic biology company that provides an integrated suite of cells, genes, and software to enable advanced genetic design and manufacture of therapies. Their platform includes engineered host cells, a genetic parts library, and cloud-based design software, allowing clients to develop custom cell lines and optimize genetic constructs. Asimov differentiates itself through its comprehensive approach, combining synthetic biology with computational tools, and has achieved significant traction with partnerships across the biotech industry, including over 25 companies from small biotechs to large pharmaceutical firms. The company is positioned at the forefront of the synthetic biology market, leveraging AI and machine learning to enhance genetic engineering capabilities.

Ayo Ayo is an electronics design consulting firm specializing in mixed signal printed circuit board design. We provide expert consulting services to bring your electronics projects to life.

BoolSi is a command line tool designed for distributed simulations and analysis of synchronous Boolean networks, enabling users to efficiently turn any codebase into chips. The platform differentiates itself by providing a robust solution for complex simulations, catering to developers and researchers in the field of computer science and engineering. With a focus on scalability and performance, BoolSi positions itself as a valuable tool for those looking to optimize their codebases for chip design and analysis, making it a compelling option for investment in the tech sector.

Bullseye Biosciences is a biotechnology research company that operationalizes cutting-edge directed evolution technology to develop novel therapeutics for cardiometabolic, inflammation, and oncology patients. By leveraging automation and Next Generation Sequencing, they aim to address challenging drivers of human disease, positioning themselves as a leader in the biotherapeutics space. Their world-class team focuses on translating scientific advancements into effective medicines, making them a compelling option for investors interested in innovative healthcare solutions.